In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...

BERLIN -- Antibody-drug conjugates (ADCs) targeting Trop2 made a strong case as first-line standard of care for metastatic ...

Samsung Bioepis and Phrontline will co-develop two investigational antibody-drug conjugate (ADC) assets directed against ...

Boehringer Ingelheim and AimedBio collaborate on ADC therapy targeting a protein involved in cancer growth, aiming to enhance ...

Lugano/Berlin 18 October 2025 - In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...

While sentiment in the local biotech sector is improving, a plethora of smaller revenue-generating stocks remain deeply ...

Collaboration and license agreement will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with a new asset expected to enter first-in-human studies next year.New, potentially ...

Orum Therapeutics (“Orum” or the “Company”) (KRX: 475830), a public biotechnology company pioneering the field of degrader-antibody conjugates (DACs), today announced the appointment of Dorin Toader, ...

AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) came out of the blocks strongly at the ESMO congress with ...

But for the intervention of the Federación Internacional de Abogadas - Federation of International Women Lawyers (FIDA), the raping-spree and assault on a ...

AimedBio sells ADC drug technology to Boehringer Ingelheim for up to 1.4 trillion won AimedBio licenses next‑gen ADC to ...